WO2008109350A3 - Nucleic acid compounds for inhibiting il6 gene expression and uses thereof - Google Patents
Nucleic acid compounds for inhibiting il6 gene expression and uses thereof Download PDFInfo
- Publication number
- WO2008109350A3 WO2008109350A3 PCT/US2008/055333 US2008055333W WO2008109350A3 WO 2008109350 A3 WO2008109350 A3 WO 2008109350A3 US 2008055333 W US2008055333 W US 2008055333W WO 2008109350 A3 WO2008109350 A3 WO 2008109350A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- gene expression
- inhibiting
- acid compounds
- mdrna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Abstract
The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing IL6 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an IL6 mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an IL6 gene in a cell or in a subject to treat an IL6-related disease.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009212920A AU2009212920A1 (en) | 2007-03-02 | 2009-09-01 | Nucleic acid compounds for inhibiting gene expression and uses thereof |
US12/552,082 US20100105134A1 (en) | 2007-03-02 | 2009-09-01 | Nucleic acid compounds for inhibiting gene expression and uses thereof |
US13/327,545 US20130011922A1 (en) | 2007-03-02 | 2011-12-15 | Nucleic acid compounds for inhibiting gene expression and uses thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93494007P | 2007-03-02 | 2007-03-02 | |
US60/934,940 | 2007-03-02 | ||
US93493007P | 2007-03-16 | 2007-03-16 | |
US60/934,930 | 2007-03-16 | ||
US97079607P | 2007-09-07 | 2007-09-07 | |
US60/970,796 | 2007-09-07 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/055341 Continuation-In-Part WO2008109354A1 (en) | 2007-03-02 | 2008-02-28 | Nucleic acid compounds for inhibiting il18 gene expression and uses thereof |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/055382 Continuation-In-Part WO2008109379A1 (en) | 2007-03-02 | 2008-02-28 | Nucleic acid compounds for inhibiting il17a gene expression and uses thereof |
US12/552,082 Continuation-In-Part US20100105134A1 (en) | 2007-03-02 | 2009-09-01 | Nucleic acid compounds for inhibiting gene expression and uses thereof |
AU2009212920A Division AU2009212920A1 (en) | 2007-03-02 | 2009-09-01 | Nucleic acid compounds for inhibiting gene expression and uses thereof |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2008109350A2 WO2008109350A2 (en) | 2008-09-12 |
WO2008109350A9 WO2008109350A9 (en) | 2008-12-11 |
WO2008109350A3 true WO2008109350A3 (en) | 2009-02-19 |
WO2008109350A4 WO2008109350A4 (en) | 2009-04-23 |
Family
ID=39739026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/055333 WO2008109350A2 (en) | 2007-03-02 | 2008-02-28 | Nucleic acid compounds for inhibiting il6 gene expression and uses thereof |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2009212920A1 (en) |
WO (1) | WO2008109350A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008049078A1 (en) | 2006-10-18 | 2008-04-24 | Nastech Pharmaceutical Company Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
AU2008247488B2 (en) * | 2007-05-04 | 2014-02-27 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
US8318693B2 (en) | 2008-09-02 | 2012-11-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of mutant EGFR gene |
CN106636090B (en) * | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | SiRNA, recombinant expression CAR-T carrier and its construction method of human leukocyte interleukin 6 and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056153A2 (en) * | 2005-11-04 | 2007-05-18 | Nastech Pharmaceutical Company Inc. | Peptide-dicer substrate rna conjugates as delivery vehicles for sirna |
WO2007107162A2 (en) * | 2006-03-23 | 2007-09-27 | Santaris Pharma A/S | Small internally segmented interfering rna |
WO2008049078A1 (en) * | 2006-10-18 | 2008-04-24 | Nastech Pharmaceutical Company Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
-
2008
- 2008-02-28 WO PCT/US2008/055333 patent/WO2008109350A2/en active Application Filing
-
2009
- 2009-09-01 AU AU2009212920A patent/AU2009212920A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056153A2 (en) * | 2005-11-04 | 2007-05-18 | Nastech Pharmaceutical Company Inc. | Peptide-dicer substrate rna conjugates as delivery vehicles for sirna |
WO2007107162A2 (en) * | 2006-03-23 | 2007-09-27 | Santaris Pharma A/S | Small internally segmented interfering rna |
WO2008049078A1 (en) * | 2006-10-18 | 2008-04-24 | Nastech Pharmaceutical Company Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
Non-Patent Citations (5)
Title |
---|
BAEZA-RAJA B. ET AL.: "p38 MAPK-induced Nuclear Factor kB activity is required for skeletal muscle differentiation: role of Interleukin-6", MOLECULAR BIOLOGY OF THE CELL, vol. 15, April 2004 (2004-04-01), pages 2013 - 2026, XP002505646 * |
BRAMSEN JESPER B. ET AL.: "Improved silencing properties using small internally segmented interfering RNAs", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 35, no. 17, 28 July 2007 (2007-07-28), pages 5886 - 5897, XP002458184, ISSN: 0305-1048 * |
HAGERMAN K.R. AND HAGERMAN P.J.: "Helix rigidity of DNA: the meroduplex as an experimental paradigm", JOURNAL OF MOLECULAR BIOLOGY, vol. 260, 1996, pages 207 - 223, XP002484999 * |
LEUSCHNER P J F ET AL: "Cleavage of the siRNA passenger strand during RISC assembly in human cells", EMBO REPORTS, XX, XX, vol. 7, no. 3, 1 March 2006 (2006-03-01), pages 314 - 320, XP002467845 * |
MILLS JANINE B. ET AL.: "Origin of the intrinsic rigidity of DNA", NUCLEIC ACIDS RESEARCH,, vol. 32, no. 13, 1 January 2004 (2004-01-01), pages 4055 - 4059, XP002484664 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008109350A2 (en) | 2008-09-12 |
AU2009212920A1 (en) | 2009-10-01 |
WO2008109350A9 (en) | 2008-12-11 |
WO2008109350A4 (en) | 2009-04-23 |
AU2009212920A8 (en) | 2009-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008109465A3 (en) | Nucleic acid compounds for inhibiting fgfr gene expression and uses thereof | |
WO2008109381A3 (en) | Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof | |
WO2009029293A3 (en) | Nucleic acid compounds for inhibiting myc gene expression and uses thereof | |
WO2007128477A3 (en) | SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION | |
WO2010017319A3 (en) | Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof | |
WO2008109516A3 (en) | Nucleic acid compounds for inhibiting ras gene expression and uses thereof | |
WO2010006973A3 (en) | Compositions and methods for inhibiting expression of tgf-beta receptor genes | |
WO2008109352A8 (en) | Nucleic acid compounds for inhibiting akt gene expression and uses thereof | |
WO2010017311A3 (en) | Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof | |
WO2008109350A3 (en) | Nucleic acid compounds for inhibiting il6 gene expression and uses thereof | |
WO2008109375A3 (en) | Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof | |
WO2008109372A3 (en) | Nucleic acid compounds for inhibiting pdgf gene expression and uses thereof | |
WO2008109546A3 (en) | Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof | |
WO2008109366A3 (en) | Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof | |
WO2008109548A3 (en) | Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof | |
WO2008109506A8 (en) | Nucleic acid compounds for inhibiting jun gene expression and uses thereof | |
WO2008109443A3 (en) | Nucleic acid compounds for inhibiting cdk2 gene expression and uses thereof | |
WO2011139843A3 (en) | Multi-sirna compositions for reducing gene expression | |
WO2008109558A3 (en) | Nucleic acid compounds for inhibiting tlr gene expression and uses thereof | |
WO2008109495A3 (en) | Nucleic acid compounds for inhibiting cd40 gene expression and uses thereof | |
WO2008109487A3 (en) | Nucleic acid compounds for inhibiting mme gene expression and uses thereof | |
WO2008109493A3 (en) | Nucleic acid compounds for inhibiting cd19 gene expression and uses thereof | |
WO2008109364A3 (en) | Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof | |
WO2008109368A3 (en) | Nucleic acid compounds for inhibiting vegfr gene expression and uses thereof | |
WO2008109382A8 (en) | Nucleic acid compounds for inhibiting pkn3 gene expression and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08730993 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08730993 Country of ref document: EP Kind code of ref document: A2 |